Test Price
750 AED✅ Home Collection Available
HLA‑B*57:01 Genotyping (Abacavir Hypersensitivity) – UAE Pharmacogenetic Screening
Executive Summary & Core Metrics
Executive Summary
Mandatory DHA‑mandated pharmacogenetic screening to predict abacavir hypersensitivity. Performed with Sanger Sequencing (gold standard) at ISO‑accredited labs. Results in 7 working days.
- ✓Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO 9001:2015 Accredited Processing.
- ✓Premium Logistics: VIP Mobile Phlebotomy & Temperature‑Controlled Cold‑Chain Home Collection (Available daily from 8 AM to 11 PM).
- ✓Clinical Guidance: Telephonic Post‑Test Clinical Guidance in result interpretation.
- ✓Insurance: Direct Billing Verification via WhatsApp +971 54 548 8731.
Test Overview & Methodology
HLA‑B*57:01 Genotyping is a pharmacogenetic screening test that identifies the presence of the HLA‑B*57:01 allele, which is strongly associated with life‑threatening hypersensitivity reactions to the antiretroviral drug abacavir. The test is mandatory in the UAE before initiating abacavir therapy, in accordance with DHA pharmacovigilance protocols. Methodology: Sanger Sequencing – the gold standard for high‑resolution allele detection.
| Feature | DNA Labs UAE | Closest Alternative |
|---|---|---|
| Methodology | Sanger Sequencing (Gold Standard) | PCR‑SSP (lower resolution) |
| TAT | 7 Working Days | 10–14 Days |
| Accreditation | ISO 9001:2015 (Cert: INT/EGQ/2509DA/3139) | May lack DHA‑specific license |
Physician Insight & Safety Protocols
“As a DHA‑licensed Consultant Medical Geneticist, I underscore that HLA‑B*57:01 genotyping is a mandatory pre‑prescription safety measure for abacavir. A negative result provides a high negative predictive value, but clinicians must remain vigilant for rare non‑HLA‑B*57:01 mediated reactions.”
— Dr. Lina Osama Zaki Quteineh, DHA Registration ID: 9294403
Advisory
No special preparation required. Inform your physician of any current medications. Do not discontinue prescribed therapy without medical consultation. Results must be interpreted alongside full clinical evaluation.
Patient Safety Exclusion Criteria & Emergency Red Flags
- Acute febrile illness or active infection – reschedule after recovery.
- Pregnancy or planned surgery – consult physician; test may be deferred or require additional consent.
- Children under 18 must be accompanied by a legal guardian with valid Emirates ID, in compliance with UAE data protection and health information laws.
- If you develop sudden rash, blisters, facial swelling, or difficulty breathing while on abacavir, seek emergency care immediately regardless of genotype result.
Patient FAQ & Clinical Guidance
1. Why is this test mandatory before starting abacavir therapy in the UAE?
The HLA‑B*57:01 allele is strongly linked to severe abacavir hypersensitivity; the DHA mandates screening to prevent life‑threatening drug reactions. A negative result confirms safe use of abacavir.
2. Can I still take abacavir if my result is positive?
A positive result means abacavir is contraindicated. Your physician will switch you to a safe alternative antiretroviral regimen. The test guides alternative therapy selection.
3. How is the test performed and how long until I receive the report?
A single blood draw (5 mL) is collected via VIP mobile phlebotomy at your home or in our facility. Results are ready within 7 working days, with a detailed clinical report provided.
UAE Regulatory & Data Privacy Adherence
Regulatory Compliance
This test is performed in full compliance with:
- Federal Decree‑Law No. 45 of 2021 on Personal Data Protection (PDPL).
- Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields.
- Federal Decree‑Law No. 4 of 2016 on Medical Liability.
- DHA Licensing and quality standards for laboratory services.
Your genetic data is encrypted, anonymized, and never shared with third parties without explicit consent.
Clinical & Logistical Metadata
| Test Name | HLA‑B*57:01 Genotyping (Abacavir Hypersensitivity) |
| Price (AED) | 750 AED |
| Turnaround Time | 7 Working Days |
| Sample Type / Matrix | Peripheral Whole Blood (5 mL) |
| Methodology Used | Sanger Sequencing |
| ICD‑10‑CM Code | Z13.89 (Encounter for screening for genetic disease) |
| LOINC Code | 90839‑9 (HLA‑B*57:01 gene mutation analysis in Blood) |
| DHA Facility License & Laboratory Address | License No. 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians